Wrap it up everyone. CB-03-01 is another failed treatment 9/17/2025
CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity PP405: Regrows Hair In 8 Weeks. Is This The Miracle Cure?
PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.
community Most promising cures for baldness as of May 2026
PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.
community How likely do you think it is for PP405 to come out?
PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.
community Switch from fin to dut and its worse
Switching from finasteride to dutasteride can worsen hair loss for some men due to increased testosterone levels. Topical treatments like RU58841 and Pyrilutamide are suggested to counteract these effects, but individual responses vary.
community Currently Trending Twitter Post: Clascoterone Hailed as New Cure
Clascoterone is being discussed as a promising new hair loss treatment, showing significant improvement in trials. Despite this, skepticism persists about its effectiveness, cost, and side effects, with some users preferring minoxidil and finasteride.
community He is claiming, he can treat alopecia
A user claims a product can treat alopecia, but others are skeptical, calling it a scam due to lack of evidence and transparency. The product is said to inhibit Type II 5-αr by 22.9%, but is considered weaker than existing DHT blockers.
Related Research
6 / 6 results
research Role of the Wnt signaling pathway in keratoacanthoma
This study concluded that the Wnt signaling pathway does not significantly influence human keratoacanthoma development, but the overexpression of Sox9 suggests alternate signaling involvement.
research A systematic summary of survival and death signalling during the life of hair follicle stem cells
This review examines the life cycle, biomarkers, and functions of hair follicle stem cells, emphasizing their role in hair loss therapy and other skin and hair disorders, but reports no new clinical results.
research Recent advances in drug repositioning and rediscovery for different therapeutic activities utilizing updated technological approaches
This review outlines drug repurposing as an efficient, low-cost strategy to identify new uses for existing drugs, highlighting various computational and experimental approaches as well as publicly available databases to aid in personalized pharmacotherapy.
research Malnutrition and Allergies: Tipping the Immune Balance towards Health
This review highlights that malnutrition, including deficiencies in proteins and micronutrients, may exacerbate allergic conditions like dermatitis and asthma by promoting inflammation, while adequate micronutrient intake supports regulatory immune responses.
research NovelPAX9mutation associated with syndromic tooth agenesis
This study found a novel PAX9 gene mutation that may cause tooth agenesis and trichodysplasia in a studied family.
research IMMUNOLOGICAL AND SOME BIOLOGICAL BIOMARKERS INVESTIGATION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
This study found that all examined biomarkers and clinical features were elevated in systemic lupus erythematosus patients, particularly ANA and Anti-dsDNA autoantibodies, but no single biomarker was sensitive or specific enough for diagnosis.